OTC: SKYE - Skye Bioscience, Inc.

Yield per half year: -52.29%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Skye Bioscience, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Skye Bioscience, Inc.

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc.

more details
and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2015-04-02
ISIN US83086J1016
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://skyebioscience.com
Цена ао 2.43
Change price per day: 0% (2.5)
Change price per week: -1.57% (2.54)
Change price per month: -18.3% (3.06)
Change price per 3 month: -23.78% (3.28)
Change price per half year: -52.29% (5.24)
Change price per year: -81.48% (13.5)
Change price per 3 year: +6 310.26% (0.039)
Change price per 5 year: +2 740.91% (0.088)
Change price per 10 year: 0% (2.5)
Change price per year to date: -4.94% (2.63)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV -9.73 0
P/E 0 0
EV/EBITDA -1.11 0
Total: 2.5

Efficiency

Title Value Grade
ROA, % -315.27 0
ROE, % 1765.85 10
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.3407 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % -777.38 0
Yield EPS, % -92741.23 0
Total: 2
More

ETFShare, %Profitability for 1 year, %Dividends, %
iShares Micro-Cap ETF 0.01366 17.09 1.54048
iShares Russell 2000 Growth ETF 0.00062 38.04 0.6026
0.0127.571.07



Head Job title Payment Year of birth
Mr. Punit S. Dhillon B.A. Executive Chairman, President, CEO & Secretary 720k 1980 (45 years)
Dr. Christopher G. Twitty Ph.D. Chief Scientific Officer N/A 1973 (52 years)
Mr. Tu Diep M.Sc. Chief Development Officer N/A 1981 (44 years)
Dr. Puneet S. Arora FACE, M.D., M.S. Chief Medical Officer

Address: United States, San Diego. CA, 11250 El Camino Real - open in Google maps, open in Yandex maps
Website: https://skyebioscience.com